January 18, 2021


The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (Market Insight Reports) —
Selbyville, Delaware. The Automotive Transmission Market report upholds the future market predictions related to Automotive Transmission market size, revenue, production, Consumption, gross margin and other substantial factors. It also examines the role of the prominent Automotive Transmission market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Automotive Transmission market, the report also offers a full study of the future trends and developments of the market.

The global Automotive Transmission Market is anticipated to reach around USD 304.5 billion by 2026 according to a new research published by The marker research report. The diesel fuel type dominated the global market in 2017. In 2017, Asia-Pacific accounted for the majority share in the global automotive transmission market.

Request a sample Report of Automotive Transmission Market Analysis Report at: https://www.marketstudyreport.com/request-a-sample/1695167?utm_source=marketwatch&utm_medium=PC

The significant increase in demand for passenger and commercial vehicles, and growth in global automotive industry boosts the demand for automotive transmission in the coming years. The demand for luxury and comfortable vehicles has increased significantly, especially from the emerging economies driving the automotive transmission market growth. Consumers prefer comfortable and enhanced driving experience, which boosts the automotive transmission market. The introduction of stringent government regulations regarding carbon emissions has encouraged market players to launch efficient automotive transmission systems. New emerging markets, emerging consumer demographics, and stringent government regulations would provide growth opportunities for this market in the coming years.

In 2017, Asia-Pacific accounted for the highest share in the global automotive transmission market. The governments in the region have introduced stringent regulations regarding vehicular emissions owing to environmental concerns. The growing demand for automobiles in the region, established automotive industry, and technological advancements would accelerate the demand for automotive transmission systems during the forecast period. The increasing economic growth, and increasing demand from countries such as China and India to further increase the adoption of automotive transmissions in the region. Expansion of global players into these countries to tap market potential boosts the market growth. The high penetration of electric vehicles in the region promotes the adoption of automotive transmissions in the coming years. Asia-Pacific dominates the electric vehicle market due to the increasing population of vehicles and adoption of vehicular emission standards of the U.S. and European Union by Asia-Pacific countries. Moreover, concerns about rising pollution levels have accelerated the adoption of electric vehicles market in this region, thereby supporting the growth of the automotive transmission market.

The companies operating in the market include Magna International, Allison Transmission Inc., Eaton Corporation PLC, Continental AG, Schaeffler AG, Jatco Ltd, ZF Friedrichshafen AG, Aisin Seiki Co., Ltd., BorgWarner Inc., and GKN PLC. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Global Automotive Transmission Market: Drivers and Restraints: This section of the Automotive Transmission Market Analysis report


CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has completed its at-the-market (ATM) offering program initiated during the third quarter, generating gross proceeds of $50.0 million. Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. acted as placement agents for the offering.

In addition, Bicycle announced that it has closed a financing with Hercules Capital, Inc. (NYSE: HTGC) for a term loan of up to $40.0 million in two tranches. Under the terms of the loan and security agreement, an initial tranche of $30.0 million will be fully available at the loan closing, with a minimum draw of $15.0 million.

“I am pleased to announce the successful utilization of our ATM program and our flexible financing with Hercules, which have further strengthened our balance sheet as we prepare for multiple clinical catalysts in the coming year. Over the course of 2020, we have continued to execute on our financing strategy, generating approximately $120 million, over half of which was non-dilutive and the remainder was pursuant to our ATM program,” said Lee Kalowski, President and Chief Financial Officer of Bicycle Therapeutics. “These financings allow us to continue progressing our three clinical programs, support clinical development of our lead immuno-oncology candidate BT7480, expected to start next year, and extend our cash runway well into the first half of 2023. We believe we have the financial resources to advance our clinical and pre-clinical oncology pipeline with the aim of potentially shifting the treatment paradigm for patients with cancer who have limited therapeutic options.”

Bicycle plans to use the proceeds of the financings to advance its oncology pipeline of Bicycle Toxin Conjugates and immuno-oncology candidates through multiple clinical milestones expected in 2021, including interim updates from the ongoing Phase IIa trial of BT1718, Phase I/II trial of BT5528 and Phase I/II trial of BT8009, as well as the initiation of a Phase I/II trial of BT7480 and advancement of IND-enabling studies for BT7455.

The securities described above were offered by Bicycle pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (the “SEC”), which the SEC declared effective on June 15, 2020. A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Additional information about the debt facility with Hercules will be contained in a future Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor may there be any sale of Bicycle’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state or jurisdiction.

About Bicycle Therapeutics